Can LAI-CAB Sustain Long-Term PrEP Use?

• by Andrea Surnit

• July 17, 2026

Age-specific hospitalization dynamics during a measles outbreak in Nyanza District, Southern Province, Rwanda, 2026: A survival analysis with implications for clinical management

• by Frederic Ntirenganya, Ines Itanga, Sandrine Uwamahoro, Bruce Rwagitinywa, Jean Luc Benimana, Hugues Valois Mucunguzi, Edouard Ruseesa, Emerance Hirwa Igihozo, Edson Rwagasore

• August 20, 2026

Diagnostic accuracy of rapid diagnostic tests for vibrio cholerae serogroups O1 and O139: A systematic review and meta-analysis

• by Xitong Yao, Han Wang, Kuo Jiang, Shengyuan Wang, Wenjun Li, Zhun Wang, Yanfei Qi

• July 15, 2026

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

• by Teraya Smith

• October 9, 2026

• 2 min